Physician profile
Mark J Round
NPI 1265477640
$8,989.45
in general payments reported to CMS, 2019-2025
42 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $1,129 · 2021: $1,472 · 2022: $1,444 · 2023: $1,570 · 2024: $1,195 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,835.50 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,929.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,304.63 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,031.78 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $695.26 | 2019-2025 | Jardiance, Spiriva Respimat, Spiriva |
| Pfizer INC. | $623.55 | 2019-2025 | |
| Amgen INC. | $375.11 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $366.46 | 2021-2025 | |
| Lilly USA, LLC | $336.44 | 2019-2025 | Mounjaro, Emgality, Kisunla |
| Novo Nordisk INC | $330.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Antares Pharma, INC. | $242.69 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Otsuka America Pharmaceutical, INC. | $173.42 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $149.78 | 2019-2024 | Gattex |
| Janssen Pharmaceuticals, INC | $141.85 | 2019-2022 | |
| Esperion Therapeutics, INC. | $141.46 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $112.14 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Round listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.